GENEVA, SWITZERLAND / ACCESSWIRE / December 16, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“ Relief “), announced today that it has filed a registration statement on Form 20-F with the United States Securities and Exchange Commission (“ SECOND “) to register Relief as a reporting company under the Securities Exchange Act of 1934. The registration statement is being filed to begin the process of uplisting the US Level 1 Certificate of Deposit of Relief (“ ADR “) in the United States to a Level 2 ADR program and is part of Relief’s ongoing efforts to list its ADRs on the NASDAQ Stock Market during the first half of 2022. NASDAQ listing will not take place until after the ‘entry into force of the registration statement, which is under review by the SEC, and the filing by Relief of an application for registration with the NASDAQ, which has not yet taken place. its ADRs to the NASDAQ stock market.

Relief’s ADR program complements the existing primary listing of its ordinary shares on the SIX Swiss Exchange. Relief’s ordinary shares are listed on the SIX Swiss Exchange under the symbol “RLF” and are listed in the United States on the OTCQB market under the symbol “RLFTF”. Relief’s ADRs, which represent one hundred and fifty (150) common shares of Relief, currently trade on the US over-the-counter market under the symbol “RLFTY”.

The filing of the registration statement on Form 20-F by exemption is not part of an offer of securities. Therefore, Relief will not receive any proceeds from its current ADR program.

This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States or any other jurisdiction, nor will there be any ‘offering or selling securities in the United States or any other jurisdiction in which such offering, solicitation or sale would be illegal unless registered and / or qualified under applicable securities laws. This press release does not constitute a prospectus within the meaning of art. 35 of the Federal Law on Financial Services of June 15, 2018, as amended (“FinSA”), or art. 27 and following. of the SIX Swiss Exchange Listing Rules. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any Relief securities in or to Switzerland within the meaning ofFinSA. In addition, ADRs have not been registered under the Securities Act of 1933, as amended (the “Act”), and no public offering of securities will be made in the United States except by way of a prospectus meeting made available by Relief which contains detailed information on Relief and its management, as well as financial statements meeting the requirements of the Law.

Instructions for converting Relief common stock into Relief ADR are posted on Relief’s website at


Relief primarily focuses on drug-based clinical stage programs with a history of clinical trials and use in human patients or a strong scientific rationale. Relief’s drug candidate, RLF-100 (TM) (aviptadil), a synthetic form of vasoactive intestinal peptide (“VIP”), is currently in advanced clinical trials in the United States for the treatment of respiratory impairment due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a collaboration and license agreement with Acer Therapeutics for the development and commercialization of ACER-001 globally. ACER-001 is a proprietary, taste-masked, immediate-release powder formulation of sodium phenylbutyrate (NaPB) for the treatment of urea cycle disorders and maple syrup disease. In addition, the recent acquisitions by Relief of APR Applied Pharma Research SA and AdVita Lifescience GmbH, provide Relief with a diverse portfolio of commercialized and development-phase programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and listed in the United States on the OTCQB under the symbols RLFTF and RLFTY. For more information, visit Follow us on LinkedIn.

Jack weinstein
Chief Financial Officer and Treasurer
[email protected]

Rx communication group
Michael miller
+ 1-917-633-6086
[email protected]

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements regarding RELIEF THERAPEUTICS Holding SA. Such statements involve certain risks, uncertainties and other known and unknown factors, including (i) whether the registration statement will come into effect, (ii) whether a market will develop for Relief’s ADRs, (iii) whether, whether the Relief ADRs are traded on the United States, they will become eligible to be listed on the NASDAQ Stock Market, and the timing of such listing, and (iv) the risks discussed in RELIEF THERAPEUTICS Holding SA press releases, deposits with SIX and deposits with the United States. Exchange Commission, which could cause a substantial difference between the actual results, financial position, performance or achievements of RELIEF THERAPEUTICS Holding SA and the future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication on this date and does not undertake to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

THE SOURCE: Relief Therapeutics Holdings AG

See the source version on